Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192517 | 0.98 | OPRL1 (0.54) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL2346342 | 0.98 | OPRL1 (0.54) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL2192474 | 0.98 | OPRL1 (0.54) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL4206116 | 0.95 | OPRL1 (0.56) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL23343753 | 0.91 | OPRL1 (0.65) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL9133740 | 0.88 | OPRL1 (0.46) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| Hexane SCHEMBL27427100 | 0.87 | OPRL1 (0.50) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| Cyclohexanol SCHEMBL596691 | 0.86 | OPRL1 (0.45) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL14379186 | 0.84 | OPRL1 (0.50) | OPRL1OPRM1OPRD1OPRK1MAOA | |
| SCHEMBL7802826 | 0.83 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496890-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003051353-A1 | SUBSTITUTED BETA-AMINOALCOHOLS USED AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-06-26 | — | — | WO | claimed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3912620-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | PACIFIC NORTHWEST RESEARCH INSTITUTE (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3204120-B1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | PACIFIC NORTHWEST RES INSTITUTE (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200338036-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | PACIFIC NORTHWEST RESEARCH INSTITUTE | 2020-10-29 | — | — | US | disclosed |
| US-10751317-B2 | Methods and compositions for increasing the potency of antifungal agents | PACIFIC NORTHWEST RESEARCH INSTITUTE (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170296502-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | PACIFIC NORTHWEST RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-20170296502-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | PACIFIC NORTHWEST RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583532-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | Astrazeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004045614-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751317-B2 | Methods and compositions for increasing the potency of antifungal agents | ERG28, DPM1, CYP51A1 | OPRL1 4874/4885OPRM1 4025/4885OPRD1 4324/4885 |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | OPRL1 2177/4885OPRM1 4338/4885OPRD1 1926/4885 |
| US-20200338036-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | OPRL1 4874/4885OPRM1 4025/4885OPRD1 4324/4885 |
| US-20170296502-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | OPRL1 4874/4885OPRM1 4025/4885OPRD1 4324/4885 |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | OPRL1 4559/4885OPRM1 4471/4885OPRD1 4305/4885 |
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | GCK, GCKR, GALK1 | OPRL1 3245/4885OPRM1 3464/4885OPRD1 3016/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | OPRL1 2990/4885OPRM1 2267/4885OPRD1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.